Global Search

Search articles, concepts, and chapters

Robert Matthieu P

4 articles in GJC

4 articles in GJC

2.

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65 -mediated inherited retinal dystrophy.

Daruich Alejandra, Rateaux Maxence, Batté Emilie, de Vergnes Nathalie, Valleix Sophie, Robert Matthieu P et al.

Br J OphthalmolJan 202510 citationsCase Series

Pediatric RPE65 gene therapy (Luxturna) significantly improved visual acuity at 12 months. Despite some complications, these gains in visual function were maintained, highlighting its clinical benefit.

All 4 articles loaded